GILEAD SCIENCES INC's Q3 2026 13F: no position changes
Form 13F-HR for the quarter ended Sep 30, 2026 · filed Nov 5, 2026 · 5 reported positions · accession 0001123292-26-001479
What changed this quarter
No equity positions were opened, closed, increased or reduced in this filing.
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 100.0% of the equity book
No changes in the top 10 this quarter
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | Arcus Biosciences Inc. (RCUS) | 58.8% | 55.5% | |
| 2 | Lakefront Biotherapeutics (LKFT) | 30.3% | 34.2% | |
| 3 | Assembly Biosciences Inc. (ASMB) | 8.3% | 8.0% | |
| 4 | Kyverna Therapeutics Inc. (KYTX) | 2.2% | 1.9% | |
| 5 | Xilio Therapeutics Inc. (XLO) | 0.4% | 0.4% |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).